Whats new
Whats new.
CLSA - Higher dosing showing promise; MBC efti+chemo dose escalation complete response, no safety concerns; Rated BUY, A$0.95 (Analyst: Andrew Paine)
May 16th 2024
For a copy of this research report please contact your CLSA advisor